Regeneron stock analysis
Regeneron passes 6 of 8 fundamental tests, a score of 8/10. On the daily chart it is in a sideways range, RSI 57, 8% below its 52-week high: range-bound: no edge either way. Its own volatility puts the likely range at $719.65–$868.85 a month from now and $570.58–$1,096 in a year (68% bands). The last two days of news lean bullish (5 positive, 0 negative stories).
Fundamentals 8/10
- Market cap
- $81.4 B
- P/E · forward
- 19.6 · 12.8
- PEG · P/B
- 1.4 · 2.5
- ROE · net margin
- +14% · +28%
- Revenue · earnings growth
- +17% · -5%
- Debt / equity
- 9%
- Dividend · beta
- 0.5% · 0.2
- Next results
- 30 Oct 2026
- ✕ ROE above 15%
- ✓ Net margin above 10%
- ✓ Revenue growing over 10%
- ✕ Earnings growing
- ✓ Debt/equity under 100%
- ✓ Positive free cash flow
- ✓ Forward P/E under trailing (earnings expected up)
- ✓ PEG under 2
Swing technicals (daily)
- Trend
- sideways · 50d above 200d
- RSI(14)
- 57
- 20 / 50 / 200-day avg
- $764.69 / $790.85 / $735.42
- 20-day breakout
- above $813.53 · below $722.02
- ATR(14)
- $21.76 (2.8% a day)
- 52-week range
- $564.00 – $859.34
- Return 3m · 6m · 1y
- +18% · +5% · +37%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | $719.65 – $868.85 (-9% / +10%) |
| 3 mo | $671.70 – $930.88 (-15% / +18%) |
| 6 mo | $627.80 – $995.97 (-21% / +26%) |
| 1 year | $570.58 – $1,096 (-28% / +39%) |
Analysts (27): buy, mean target $863.93 (+9%)
From its own volatility (33% a year), no drift assumed: what its swings allow, not a forecast.
Regeneron news · last two days
News lean: Bullish · 5 up · 0 down- 30h agoRegeneron Says EMA Panel Recommends Approval of Updated Dosing Regimen for LibtayoMT Newswires
- 32h agoUBS lifts Regeneron stock target to USD 978.00Ad Hoc News
- 34h agoCHMP Backs Less Frequent Regeneron's Libtayo Dosing Across Approved Cancer Indications In EuropeRTTNews
- 36h agoDid Earnings Beat Just Shift Regeneron Stock Investment Narrative?Simply Wall St.
- 40h agoRegeneron stock pre-market at EUR 710.60Ad Hoc News
- 43h agoRegeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative HoldsSimply Wall St.
- 45h agoRegeneron Pharmaceuticals Insider Sold Shares Worth $3,204,376, According to a Recent SEC FilingMT Newswires
- 46h agoRegeneron Pharmaceuticals Shares Rise After UBS UpgradeMT Newswires
- 2d agoQ2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology StocksStockStory
- 2d agoUBS upgrades Regeneron Pharmaceuticals to buy from neutralFintel on MSN
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.